The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
about
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma.Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccinationChemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy?CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma.Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Recent developments in the treatment of renal cell carcinoma.Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.T-cell-based immunotherapy of autoimmune diseases.Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors.Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform.PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.Truncated Escherichia coli thioredoxin induces proliferation of human blood mononuclear cells and production of reactive oxygen species as well as proinflammatory cytokines.Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors.
P2860
Q34028464-3290B03F-C3D4-4E81-BDF4-D3CAF1BD3B4EQ34477227-8E6AD6CB-978E-43FB-9208-37E6CFCDE4FFQ34534663-5083CF04-750D-4F9B-888A-59CF0ABCD7D1Q35600299-31DB300C-2F89-42EC-9C00-A68A17DB499AQ36444444-EC80B67F-B023-48F2-AD0C-B65E75221D23Q36845810-BD2C37DD-8412-47F2-8CCC-DE9E7D56AD74Q37054587-96ADC3CF-7FBF-4B02-9396-AD0D8118C66AQ37269115-9DC53194-1D23-43B5-9453-93193788B03CQ37300942-8A9F12B5-91A0-478F-AE2C-371035DE4ECBQ37650720-5CC49260-C4AB-49CC-AA73-76D66DCC4996Q38089940-18571452-8F3B-455B-B1F4-E204A2E063B0Q38564238-B0491F5A-107E-40A4-8399-53948A66B6B6Q38772887-6CEF7A00-971D-4B2C-AE66-EA877348DF5AQ38909407-9EA72CF7-FA26-4AC8-8DEF-69BDE2EDD40BQ39143622-4A7160FA-F183-4E9D-955F-D54E6FCF2E9AQ42649288-6C403594-2780-4E2F-B2DB-0745C85E3F72Q46571584-2BB8F19B-B4ED-4B1D-891D-A8EEE5D1D3A4Q47355563-639F6139-7501-4882-8A86-AD060396D30C
P2860
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
The 20th anniversary of interl ...... of complete clinical responses
@ast
The 20th anniversary of interl ...... of complete clinical responses
@en
The 20th anniversary of interl ...... of complete clinical responses
@nl
type
label
The 20th anniversary of interl ...... of complete clinical responses
@ast
The 20th anniversary of interl ...... of complete clinical responses
@en
The 20th anniversary of interl ...... of complete clinical responses
@nl
prefLabel
The 20th anniversary of interl ...... of complete clinical responses
@ast
The 20th anniversary of interl ...... of complete clinical responses
@en
The 20th anniversary of interl ...... of complete clinical responses
@nl
P2860
P3181
P356
P1476
The 20th anniversary of interl ...... of complete clinical responses
@en
P2093
Brendon J Coventry
Martin L Ashdown
P2860
P304
P3181
P356
10.2147/CMAR.S33979
P407
P577
2012-01-01T00:00:00Z